Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Curr Cancer Drug Targets. 2013 Feb;13(2):157-64. doi: 10.2174/1568009611313020005.
Despite recent advances in our understanding of the biological basis of prostate cancer, the management of the disease, especially in the castration-resistant phase, remains a significant challenge. Deregulation of the phosphatidylinositol 3-kinase (PI3K) pathway is increasingly implicated in a number of malignancies, including prostate carcinogenesis. In this review, we detail the role of this pathway in the pathogenesis of prostate cancer and the therapeutic implications of targeting it.
尽管我们对前列腺癌生物学基础的理解最近有了进展，但该疾病的治疗，特别是在去势抵抗阶段，仍然是一个重大挑战。磷脂酰肌醇 3-激酶（PI3K）途径的失调越来越多地涉及到许多恶性肿瘤，包括前列腺癌的发生。在这篇综述中，我们详细介绍了该途径在前列腺癌发病机制中的作用以及靶向该途径的治疗意义。
